Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 451-462 |
| Journal | Trends in pharmacological sciences |
| Volume | 37 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2016 |
Fingerprint
Keywords
- IR-103722
- METIS-320768
Cite this
}
Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer. / Kroon, Jan; Kroon, Jan; Kooijman, Sander; Cho, Nam-Joon; Storm, Gerrit; van der Pluijm, Gabri.
In: Trends in pharmacological sciences, Vol. 37, No. 6, 2016, p. 451-462.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer
AU - Kroon, Jan
AU - Kroon, Jan
AU - Kooijman, Sander
AU - Cho, Nam-Joon
AU - Storm, Gerrit
AU - van der Pluijm, Gabri
N1 - review article
PY - 2016
Y1 - 2016
N2 - Currently, the clinical utility of taxane-based drug formulations in castration-resistant prostate cancer (CRPC) is severely limited by acquired chemotherapy resistance, dose-limiting toxicities, and nonresponders. Therefore, approaches to improve taxane-based chemotherapy are desperately required. In this review, we highlight the strategies that aim to overcome these limitations, such as bypassing therapy resistance, targeted drug delivery, and adequate prediction of therapy response. The involvement of the apoptotic pathway, ABC transporters, the glucocorticoid receptor (GR) axis, androgen receptor (AR) splicing, epithelial plasticity, and cancer stem cells in mediating taxane-resistance are outlined. Furthermore, passive and active targeted nanomedicinal drug delivery strategies and the use of circulating tumor cells in predicting docetaxel responses are discussed. Finally, recent advances towards clinical translation of these approaches in CRPC are reviewed.
AB - Currently, the clinical utility of taxane-based drug formulations in castration-resistant prostate cancer (CRPC) is severely limited by acquired chemotherapy resistance, dose-limiting toxicities, and nonresponders. Therefore, approaches to improve taxane-based chemotherapy are desperately required. In this review, we highlight the strategies that aim to overcome these limitations, such as bypassing therapy resistance, targeted drug delivery, and adequate prediction of therapy response. The involvement of the apoptotic pathway, ABC transporters, the glucocorticoid receptor (GR) axis, androgen receptor (AR) splicing, epithelial plasticity, and cancer stem cells in mediating taxane-resistance are outlined. Furthermore, passive and active targeted nanomedicinal drug delivery strategies and the use of circulating tumor cells in predicting docetaxel responses are discussed. Finally, recent advances towards clinical translation of these approaches in CRPC are reviewed.
KW - IR-103722
KW - METIS-320768
U2 - 10.1016/j.tips.2016.03.003
DO - 10.1016/j.tips.2016.03.003
M3 - Article
VL - 37
SP - 451
EP - 462
JO - Trends in pharmacological sciences
JF - Trends in pharmacological sciences
SN - 0165-6147
IS - 6
ER -